$FFR Income Statement | Understand Stock

$FFR

$1.11 +$0.04 (3.74%) Close

$FFR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations and Comprehensive Loss

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Product sales
Net Product Sales
License Revenue
Total product sales
EXPENSES
Cost of product sales
General and administrative
Research and development
Sales and marketing
Impairment loss on construction in progress
Goodwill, Impairment Loss
Credit loss expense - short-term note receivable
Total expenses

LOSS FROM OPERATIONS
OTHER EXPENSE (INCOME), NET
Gain on change in fair value of warrant liabilities
Gain on change in fair value of derivative liabilities
Interest expense, net
Loss on voluntary conversion of convertible debt
Gain on change in fair value of convertible debt
Interest expense
(Gain) loss on voluntary conversion of convertible debt into common stock
Interest income
Loss on issuance of convertible debt
Net loss on digital assets
Gain on voluntary conversion of convertible debt into common stock
Loss on debt extinguishment
Loss on fixed asset disposal
Loss on monthly redemptions of convertible debt into common stock
Gain on settlements of accounts payable
Other expense (income), net
Total other expense (income), net
LOSS BEFORE PROVISION FOR INCOME TAXES
PROVISION FOR INCOME TAXES
NET LOSS FROM CONTINUING OPERATIONS
INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL
Loss on disposal of discontinued operations, net of tax
Loss from discontinued operations, net of tax
Loss on disposal of discontinued operations, net of tax
LOSS FROM DISCONTINUED OPERATIONS
Foreign currency translation adjustment from discontinued operations
Other comprehensive loss
Comprehensive loss attributable to noncontrolling interest from discontinued operations
Comprehensive loss attributable to Qualigen Therapeutics, Inc.
Net loss attributable to non-controlling interest from discontinued operations
NET LOSS
Net loss per common share, basic and diluted
Weighted—average number of shares outstanding, basic and diluted
Deemed dividend arising from preferred stock and warrant down-round provision
Net loss attributable to shareholders
Net loss per common share, basic - continuing operations
Net loss per common share, diluted - continuing operations
Net loss per common share, basic - discontinued operations
Net loss per common share, diluted - discontinued operations
Total net loss per common share, basic
Total net loss per common share, diluted
Weighted-average number of shares outstanding, basic
Weighted-average number of shares outstanding, diluted

Comments